The Canadian authorities have allowed a startup to export psychedelic substances to Australia for medicinal purposes. Optimi Health Corp. is authorized by the health department to ship capsules containing psilocybin, a psychoactive substance extracted from magic mushrooms, and MDMA.
The increasing demand is not limited to the local magic mushrooms Ontario. Other countries are learning from Canada and are beginning to investigate and allow the use of serotonergic compounds for medical use.
You can buy psychedelics online in Canada confidently and unleash your inherent potential from trustworthy sources.
[toc]Major Points:
- Vancouver-based startup Optimi Health has been awarded a drug establishment license to export magic mushroom capsules to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment consists of three sessions over a period of five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a startup based in Vancouver, aims to use its certification to broaden the medicinal psychedelic market and gain a first-mover advantage.
While seven corporations have exported psilocybin, MDMA, or both, it has been exclusively for clinical trials. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and refrained from revealing the companies due to privacy concerns.
This milestone places Optimi among a handful of global suppliers, with the current market focusing more on clinical rather than recreational use.
What Does the Pill Contain?
The company has not disclosed the specific type of mushroom used in the pill, but they do work with various strains such as Albino Penis Envy and others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, experiment, and extract its psychedelic mushrooms. This quaint community of approximately 3,000 inhabitants is situated a three-hour drive east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
Evidence suggests that 1 in 5 Australians aged between 16 and 85 could endure a mental health issue. PTSD (post-traumatic stress disorder) might impact around 11% of Australians during their lifetime, and anxiety disorders are common in 17% of the population.
There’s a broad spectrum of treatment methods for mental disorders, but not all are effective for each person. Individuals who don’t respond to certain treatment modalities may struggle to find a method that works for them, making them more susceptible to their conditions.
Understanding the Process
Australia has been at the forefront of using psilocybin, allowing certified psychiatrists to employ this regulated substance in the treatment of PTSD and depression that are resistant to traditional treatments.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA confirmed these substances are safe when used in a medically supervised setting for patients with severe mental health conditions.
This shift has been revolutionary for numerous mental health professionals and researchers. The consumption of these substances will be strictly monitored; it’s not just a case of taking a pill and heading out.
The treatment protocol typically covers three sessions spanning five to eight weeks. Each session lasts about eight hours, with the therapist present with the patient throughout the process.
Canada’s Role in Psilocybin Research
Canada has become an important center for psilocybin research, greatly expanding our understanding of this compound. Health Canada, in collaboration with various institutions, is leading the study of psilocybin’s potential therapeutic applications for a range of mental health disorders.
Research institutions are no longer bound to label these substances as illegal or rely on unregulated dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
This newfound availability of substances previously deemed detrimental enables researchers to enhance their understanding of their potential advantages for many individuals.
A Cyclic Trend
The value of this discipline was first acknowledged in the 1950s for tackling mental health problems and substance misuse, including alcohol addiction. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers in this early research at the Weyburn Saskatchewan Mental Hospital, which saw significant progress under the leadership of then-premier Tommy Douglas. He provided considerable freedom to the medical community to explore their hypotheses.
Dr. Osmond and Dr. Hoffer initiated investigations with LSD, mescaline, and peyote as potential alternatives to the harsh treatments of electroshock and lobotomy. Their research took unforeseen turns as they encouraged doctors, nurses, and support staff to experiment with these substances.
Canadian Institutes of Health Research
Under the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Primary Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in terminally ill cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a deeper understanding of the potential benefits of regulated substances. This opportunity has been created by the Canadian Drugs and Substances Strategy (CDSS) launched by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have begun a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The protocol includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. This trial is considered historically important as it is the first clinical evaluation of an illicit over four decades.
Exploring Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is found in specific mushroom species. Upon ingestion, it turns into psilocin. This psilocin activates the serotonin 5-HT2a receptors present in the cortical pyramidal cells of the brain, which serve as the central processing sites.
Presently, the substance is under investigation for its potential in aiding depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective Against Depression, PTSD, and More?
The active ingredient impacts various brain areas, making it potentially beneficial for a range of mental conditions. Many patients in Canada and Australia have already experienced this therapy, and the reported results are promising, with minor side effects such as temporary anxiety or increased blood pressure.
Neurobiological Effects
- Activation of Serotonin Receptors: The substance functions as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, which plays a vital role in emotional processing and mood regulation.
- Modulation of Default Mode Network (DMN): The substance reduces activity in the DMN, promoting introspection, minimizing rigid thought patterns, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the substance stem from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depression, individuals often show reduced responsiveness to emotional stimuli. The substance increases the reaction to positive emotional stimuli in the right amygdala and decreases or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Creation of Positive Mood States: The substance fosters euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience might allow individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it can result in enduring positive changes, such as enhanced wellness, increased satisfaction with life, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Shops?
Interested in exploring how the substance might affect your mental health? Check out local magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Advantages |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, stimulates creative thinking, and increases productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports wellness and enhances overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a powerful mixture of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Acceptance of Psilocybin
Canada isn’t the only country advocating the use of magic mushrooms to treat mental health problems. Other nations, like Australia, are also embracing these hallucinogens to tackle conditions such as depression and PTSD. They procure top-quality psychedelic capsules from trusted sources. Under the right supervision, patients can significantly improve their life quality. Shroom Dudes Canada, a magic mushroom seller, offers a variety of products, ranging from tablets to LSD edibles.
Frequently Asked Questions
How are psilocybin and MDMA alike?
Both psilocybin and MDMA have therapeutic benefits, enhancing mental health. Psilocybin interacts with serotonin 2A receptors and can be effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatment. It displays potential in boosting emotional processing and
Despite being classified as a controlled substance, it can generate beneficial therapeutic results.
Who in Australia is eligible for this treatment?
Not everyone. In Australia, an individual’s eligibility for using the substance is determined after a thorough evaluation. This assessment takes into account variables such as pre-existing heart conditions and a history of psychosis. The treatment is solely available to patients who have shown no response to conventional treatments for conditions like depression, anxiety, or PTSD.
What implications does Canada’s export of mushrooms have?
Canada is positioning itself as a major player in the psychedelics market, mirroring its approach to cannabis. This could encourage more companies to produce high-quality products. As a result, Canada could emerge as a leader in the hallucinogen market, strengthening its economy and making treatments more accessible to other countries. It could also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thus ensuring safety.
Articles That Might Interest You:
